Nature 546 , 312315 (2017)
Zepbound (tirzepatide for weight management / obesity): approved later (November 2023) based on robust phase 3 obesity trials (SURMOUNT) showing weight reduction vs placebo at 72 weeks
A positive CVOT readout is what unlocks a broad cardiovascular-risk-reduction claim on the eventual label, analogous to what LEADER did for liraglutide and SELECT did for semaglutide
Like all medications though, retatrutide does cause side effects for some people
During a video consultation, your MDWatch provider reviews your medical history, current medications, and goals to determine whether Semaglutide is appropriate
Finally, even after you receive your medications, you will need to carefully review the product and its label